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Abstract Histone acetyltransferase and histone deacetylase are enzymes responsible
for histone acetylation and deacetylation, respectively, in which the histones
are acetylated and deacetylated on lysine residues in the N-terminal tail and
on the surface of the nucleosome core. These processes are considered the
most important epigenetic mechanisms for remodeling the chromatin struc-
ture and controlling the gene expression. Histone acetylation is associated
with gene activation. Sodium phenylbutyrate is a histone deacetylase in-
hibitor that has been approved for treatement of urea cycle disorders and is
under investigation in cancer, hemoglobinopathies, motor neuron diseases,
and cystic fibrosis clinical trials. Due to its characteristics, not only of histone
deacetylase inhibitor, but also of ammonia sink and chemical chaperone, the
interest towards this molecule is growing worldwide. This review aims to
update the current literature, involving the use of sodium phenylbutyrate in
experimental studies and clinical trials.
1. Introduction
The developmental biologist Conrad H.
Waddington (1905–75) is considered to have
coined the term ‘epigenetics’ in 1942[1] when
he defined it as ‘‘the branch of biology which
studies the causal interactions between genes and
their products which bring the phenotype into
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being.’’[2] The word ‘epigenetics’ derives from
epi- (Greek: epi´- over, above) and -genetics
(Greek: genetiko´B genetikos, ‘genitive’ and that
from ge´nesiB genesis, ‘origin’). Nowadays DNA
methylation and histone modifications, i.e. ace-
tylation, methylation, and phosphorylation, can
be defined as epigenetic mechanisms important
to determine when and where a gene will be
expressed. Several inhibitors and activators of
enzymes that catalyze DNA or histone modifica-
tions are considered useful as therapeutic agents,
since the imbalance of epigenetic networks is
known to cause several pathologic conditions.[3]
The human genome is packaged so as to form
the chromatin, which is made up of repetitive
units called nucleosomes. A single nucleosome
core structure can be described as a fragment of
DNA, wrapped around a histone octamer formed
by four histone partners (one H3-H4 tetramer
and two H2A-H2B dimers).[4] Histone lysine and
arginine residues are subject to post-translational
modifications – i.e. methylation, citrullination,
acetylation, ubiquitination, and sumoylation – and
the combinatorial action of these modifications
regulates the critical DNA processes, including
replication, repair, and transcription. In addition,
the enzymes that modify histone lysine and argi-
nine residues have been connected to a variety of
human diseases, including arthritis, cancer, heart
disease, diabetes mellitus, and neurodegenerative
disorders.[5] In particular, histone acetyl trans-
ferases (HATs) and histone deacetylases (HDACs)
are responsible for the histone being acetylated or
deacetylated (removal of an acetyl group from
the e-amino groups of the lysine side-chains) and
have been related to transcription, cell cycle pro-
gression, gene silencing, lymphocyte and muscle
differentiation, regulation of neuronal pheno-
type, DNA replication, and the response to DNA
damage.[6] HATs acetylate the specific lysine
residues in the amino terminals of histones, which
are thought to neutralize the positive charge gen-
erating a more open DNA conformation, thus
connecting to nucleosome remodeling and tran-
scription regulation. The change of the charge
induces a reduction in the affinity between the
histones and DNA generates a more open DNA
conformation. The histone deacetylation byHDACs
is thought to restore the positive charges on his-
tones by removing the acetyl groups and is re-
sponsible for transcriptional repression through
chromatin condensation (hyperacetylated his-
tones are linked to transcriptionally active domains,
while hypoacetylated histones are generally as-
sociated with transcriptionally silent loci).[4,7-9]
Histone deacetylase inhibitors (HDACIs) have
been classified in different classes: short-chain fatty
acid (as sodium butyrate, valproic acid, etc.), ep-
oxides (as depudecin and trapoxin), cyclic peptides,
benzamides, and hydroxamic acids (as trichostatin
A [TSA], suberoylanilide hydroxamic acid [vor-
inostat; SAHA], and LAQ824).[10] Apart from
these classic HDACIs, today, novel compounds,
such as hydroxamic acids and benzamides, are
also available.
Sodium phenylbutyrate (figure 1), a HDACI,
is an aromatic fatty acid that is converted/
oxidized in vivo into phenylacetate (PAA) by
b-oxidation.[11] In humans the so formed PAA
is eliminated by conjugation with glutamine to
form phenacetylglutamine, which is excreted in
the urine. This metabolic pathway is the mecha-
nism by which phenylbutyrate acts as an ammo-
nia scavenger in patients with urea cycle disorders
(UCDs) and hyperammonemia.[12] It has been
shown that 1 g of phenylbutyrate would allow the
removal of the equivalent of 1 g of protein.[13]
Plasma PAA and urinary phenacetylglutamine
are also endpoints of normal tyrosine metabo-
lism. In vitro, phenylbutyrate shows the ability to
induce differentiation by various mechanisms,[14]
and the US FDA has approved its clinical use in
patients with hyperammonemia. Phenylbutyrate
therapy for infants, children, and adults withUCD,
which leads to nitrogen accumulation in the form
of ammonia, must be undertaken daily and life-
long, and it is generally well tolerated and asso-
ciated with improvements in ammonia and liver
function.[15] Phenylbutyrate is relatively stable,
with a 0.8–1 hour half-life in human serum.[16] It
O−Na+
O
Fig. 1. Chemical structure of sodium phenylbutyrate (sodium
4-phenylbutanoate).
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has been shown that phenylbutyrate is able to
lower very-long-chain fatty acid levels in the
brain of mice with x-linked adrenoleukodys-
trophy, suggesting that phenylbutyrate can cross
the blood-brain barrier.[17] An experimental study
has shown its penetration into the cerebrospinal
fluid after intravenous administration in nonhu-
man primates.[18] In the US it has been proposed
as an alternative pathway for waste nitrogen ex-
cretion in female patients with ornithine trans-
carbamylase (OTC) deficiency, which is the most
common UCD.[19] Phenylbutyrate has also been
proposed during pregnancy of heterozygote
OTC-deficient females, without leading to dele-
terious consequences for the fetus.[20] The ability
of phenylbutyrate to inhibit HDACs makes it
a good choice as an anti-tumor agent able to en-
tice cellular differentiation through modification
of chromatin and reprogramming the gene ex-
pression.[21] It has been reported that phenyl-
butyrate exerts a potent anti-tumor effect in vitro,
causing growth inhibition and differentiation in
various human cancer cells such as colon carci-
noma, Burkitt lymphoma, primary acute myeloid
leukemia, retinoblastoma, prostate cancer, U138
MG, T98G, U373 MG and A-172 glioma cells,
medulloblastoma, and hepatocellular carcinoma.
Phenylbutyrate has been safely used in phase I
and II clinical trials for solid tumors and high-
grade astrocytoma, and has shown efficacy in the
treatment of different kinds of tumors, including
hormone refractory prostate cancer, hematologic
malignancy, and high grade astrocytoma.[22]
Moreover, phenylbutyrate has reduced the neu-
roinflammation and overall disease process in
multiple sclerosis cases,[23] has attenuated cere-
bral infarction and neuronal apoptosis, and im-
proved the neurologic status in a mouse model
featuring cerebral hypoxia-ischemia.[24] Its brain
permeability remains a major limitation for drug
treatment of CNS disorders, and it has been dem-
onstrated that several HDACIs, such as vorino-
stat, sodium butyrate, phenylbutyrate, MS275
and valporic acid, are able to cross the blood-
brain barrier. That is why they are considered
good candidates for treating brain and spinal
cord disorders.[25] Interestingly, a study, con-
cerning PAA and phenylbutyrate intravenous
administration in three Rhesus monkeys, has
shown high cerebrospinal fluid penetration of
both drugs, suggesting that their activity in brain
tumors, and especially in meningeal malignancy,
should be investigated; phenylbutyrate seems to
bring some advantages, since it results in expo-
sure in plasma and cerebrospinal fluid to both
active compounds.[18]
An experimental in vitro study has been con-
ducted to test sodium butyrate, phenylbutyrate
and TSA in relation to fragile X syndrome, the
most common form of inherited mental retarda-
tion. It is characterized by an abnormal expan-
sion of the repeated trinucleotide sequence CGG,
which is contained in the regulatory region of the
FMR1 gene and causes transcriptional inactiva-
tion.[26] These compounds lead to a consistent,
but modest (1–2% of wild-type levels), reactivation
of the FMR1 gene in fragile X lymphoblasts using
reverse transcription polymerase chain reaction.[27]
2. Review Criteria
We searched the literature (all articles listed
in PubMed Central up to June 2011) for both
clinical trials and experimental studies in vitro
and in vivo, involving the use of sodium phenyl-
butyrate and derivative compounds, using the
keywords ‘triButyrate’, ‘sodium phenylbutyrate’,
and ‘4-phenylbutyric acid sodium salt’. The results
have been divided into different categories, based
on the way in which these compounds are able to
interact with different pathologic conditions.
3. Phenylbutyrate and Cancer
Histone acetylation is associated with gene ac-
tivation, while deacetylation, mediated byHDACs,
is associated with gene silencing, explaining why
HDACs are considered a powerful drug tar-
get.[28] The inhibitors of HDAC modulate the
chromatin structure, which results in loosening
the chromatin and changing transcription factor
loading to the DNA,[29] modulating the expres-
sion pattern of various tumor-relevant genes for
the control of the cell cycle or apoptosis,[30,31] and
causing the inhibition of cell growth and differ-
entiation.[32-34] These inhibitors are currently
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under clinical investigation in patients with dif-
ferent types of malignancies,[35] and phenyl-
butyrate is one of someHDACIs already tested in
clinical trials in treatment of recurrent malignant
gliomas or myelodysplastic syndrome (MDS).[36,37]
The following multiple activities have been as-
signed to the ability of phenylbutyrate to protect
normal tissues: (i) the activity of an HDACI;[38]
(ii) the activity of a chemical chaperone;[39-41] and
(iii) the activity of an ammonia sink.[42,43] HDACIs,
such as phenylbutyrate, have shown a wide range
of abilities: (i) they are able to cause cell cycle
arrest in the G1 and/or G2 phase; (ii) they induce
differentiation and/or apoptosis in a variety of
cell types;[44] (iii) they induce the transcriptional
activation of certain genes, such as the one for
cyclin-dependent kinase inhibitor p21, which has
been related to tumor suppression growth and
prevention of cell cycle progression;[45,46] (iv) they
inhibit tumor growth in animal models with little
toxicity in non-tumor cells;[47] and (v) they enhance
the expression of a wide variety of transiently
transfected transgenes in tumors, both in vitro
and in vivo, through their effect on the acetylation
of histones.[46,48] The combination of p53 gene
therapy with an HDACI, for example, FR901228
(romedipsin/depsipeptide) or phenylbutyrate, has
shown enhanced therapeutic efficacy in vitro[46]
and in vivo.[49]
Phenylbutyrate can upregulate the transcrip-
tion of epigenetically silenced genes and could be
therapeutically useful for treatment of certain
types of cancer conditions.[50] Differentiating
agents in cancer therapy may potentially alter
tumor growth and progression, slow or inhibit
metastases, and/or effect response to other forms
of therapy. Among them, phenylbutyrate has
shown, in experimental tumor model systems, to
be able to exert broad effects on tumor cytostasis
and tumor differentiation, altering the gene ex-
pression for tumor growth, invasion, angiogenesis,
and immunogenicity through mechanisms of ac-
tion, such as inhibition of histone deacetylase,
hypomethylation, modification of lipid metabo-
lism, and activation of peroxisome proliferation
activator receptor.[16] The effect of phenylbutyrate
on tumor growth inhibition has been related to
several mechanisms, including differentiation and
apoptosis induction,[51] expression of silenced genes
via histone deacetylase inhibition,[16] and induc-
tion of transforming growth factor-a secretion.[52]
Particularly, the activation of c-Jun N-terminal
kinase and extracellular signal-regulated kinase,
in the mitogen-activated protein kinase path-
way, seems to mediate the pro-apoptotic effects
of phenylbutyrate.[53] Moreover, it has been re-
ported that a differentiation therapy for epithelial
malignancies may potentially alter tumor growth
and progression, slow or inhibit metastases, inhibit
angiogenesis, and/or effect response to other forms
of therapy.[54] The ability of phenylbutyrate to be a
potent cellular differentiating and cytostatic agent
has been related to DNA methylation, a strong
association with the peroxisome proliferator-
activated receptor-g and systemic glutamine de-
pletion.[55] Differentiating agents have been used
as therapy for MDS since the bone marrow, in
this condition, is hypercellular, with aberrant dif-
ferentiation and concomitant bone marrow fai-
lure. It has been reported that these agents have
three potential roles in the treatment of myeloid
neoplasms: (i) terminal differentiation of a ma-
lignant clone to clonal extinction, as in retinoic
acid induction of acute promyelocytic leukemia;
(ii) enforced clonal differentiation leading to
functional even though clonal hematopoiesis; and
(iii) prolongation of remission duration in patients
with acute myelogenous leukemia (AML) or MDS
with residual disease after chemotherapy through
suppression of proliferation of the malignant
clone.[56]
It has been shown that in rats injected with
methylnitrosourea to induce mammary cancers,
the efficacy of anti-inflammatory agents such as
phenylbutyrate, vitamin C, and diindoylmethane
to prevent mammary carcinogenesis and to in-
hibit the growth of established tumors, has been
compared with their potential to inhibit the pro-
liferation index and increase the apoptotic index
in tumor cells showing that it is not significantly
effective (reducing tumor multiplicity by <35%).[57]
Adriamycin is a potent anticancer drug that
is used for treating both hematologic and solid
tumors, although severe cardiomyopathy and heart
failure have been observed in adriamycin-treated
cancer patients due to the potent oxidative stress
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induced by this drug. In wild-type male mice of
inbred strain C57BL/6 it has been observed that
(i) phenylbutyrate (intraperitoneal 400mg/kg/day
injected 1 day before and daily after the adriamycin
injection for 2 days) significantly decreases the
adriamycin (intraperitoneal injection [20mg/kg])-
associated elevation of serum lactase dehydroge-
nase activities; (ii) it diminishes adriamycin-induced
ultrastructural damage of cardiac tissue by >70%;
(iii) it completely rescues adriamycin-caused re-
duction of cardiac function exemplified by ejec-
tion fraction and fraction shortening; and (iv) it
increases the cardiac manganese superoxide dis-
mutase protein and activity, suggesting that a
combination therapy of HDACIs and adriamy-
cin could be beneficial for treatment of cancer
and simultaneously decrease adriamycin-induced
cardiotoxicity.[58]
In vitro studies have shown that phenylbutyrate
can (i) induce differentiation and inhibit proli-
feration of AML cell lines and primary leukemic
cells;[59,60] (ii) inhibit CFU-L production from
bone marrow specimens from patients with
MDS;[60] and (iii) induce differentiation asso-
ciated with induction of p21WAF1/CIP1 expression,
hypophosphorylation of retinoblastoma protein,
and G1 arrest in the ML-1 myeloid leukemia cell
line.[59] At least some of the pharmacodynamic
effects of phenylbutyrate seem to result because
of its ability to inhibit HDACs,[61] considering
that histone acetylation contributes to the regu-
lation of the gene transcription.[62]
The in vitro effects of decitabine, phenylbutyrate
and TSA on clonogenic AML human cells have
been investigated. It has been observed that deci-
tabine and HDACIs increase the expression of
the stem cell marker CD117 for intermediate and
erythroid colonies. Decitabine and HDACIs de-
crease the expression of the other stem cell marker
CD34 and of CD64. These effects are common to
different colony subsets. The two HDACIs TSA
and S4PB differ in their effects on the expression
of some membrane molecules, and this fact is
especially seen in CD33 and CD11b. All three
drugs modulate erythroid differentiation. Both
decitabine and HDACIs decrease CD71 ex-
pression of non-erythroid colonies and increase
its expression for mature erythroid colonies. The
authors conclude that decitabine and the two
HDACIs alter AML cell expression of differ-
entiation markers, but the drugs do not have any
major influence on cell cycle distribution.[63]
Burkitt and Ljungman,[64] after demonstrating
that a subset of head and neck cancer cell lines
have a defective Fanconi anemia DNA damage
response pathway, which correlates with cisplatin
sensitivity, have showed that phenylbutyrate
sensitizes human cells to cisplatin (cisplatin is a
widely used chemotherapeutic agent used against
many different types of tumors, but unfortunately
tumors initially responsive to it later acquire re-
sistance). The same authors observe that phenyl-
butyrate (sodium phenylbutyrate 2mmol/L for
48 hours) sensitizes cisplatin-resistant head and
neck cancer cell lines UM-SCC-1, -6, -25 to cis-
platin by inhibiting the Fanconi Anemia (FA)/
Breast Cancer (BRCA) pathway through the down-
regulation of BRCA1 as well as by an FA/BRCA-
independent mechanism. Therefore, they suggest
that the cisplatin-sensitizing effect of phenylbutyrate
is related to its role in targeting the expression of the
apoptosis-antagonist B-cell lymphoma – extra large
(Bcl-XL).[64]
Bandres et al.,[65] after identifying five micro-
RNAs (miRNAs) downregulated in patients with
colorectal cancer (CRC) and located around/on a
cytosine-phosphate-guanine (CpG) island, have
observed that treatment with a DNA methyl-
transferase inhibitor (5-aza-20-deoxycytidine)
and phenylbutyrate have restored the expression
of the three miRNAs hsa-miR-9, hsa-miR-129,
and hsa-miR-137 in three CRC cell lines. The
expression of hsa-miR-9 is inversely correlated
with the methylation of their promoter regions as
measured bymethylation-specific polymerase chain
reaction (PCR) [MSP] and bisulfate sequencing.
Moreover, the methylation of the hsa-miR-9-1,
hsa-miR-129-2, and hsa-miR-137 CpG islands is
frequently observed inCRC cell lines and in primary
CRC tumors, but not in normal colonic mucosa.
Finally, themethylation of hsa-miR-9-1 is associated
with the presence of a lymph node metastasis. This
study shows thatmiRNA-specific hypermethylation
in CRC and histone-deacetylation could be an
important molecular mechanism, as it causes the
global downregulation of miRNAs. miRNA gene
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methylation could be considered as a useful tumor
marker considering the high frequency of miRNA
hypermethylation found in CRC cancer.[65]
Hurtubise et al.[66] have observed that phenyl-
butyrate, among other HDACIs (MS-275, tri-
chostatin-A, LAQ824, and depsipeptide), has
enhanced the antineoplastic action of 5-aza-20-
deoxycytidine (5AZA-CdR; a potent inhibitor of
DNA methylation that has been approved for
treatment of hematologic malignancies and is able
to reactivate the expression of silenced tumor sup-
pressor genes [TSGs]) on Ewing sarcoma cells.
Connexin (Cx) protein deregulation is believed
to be involved in the carcinogenesis process and
to play a key role in gap junction intercellular
communication,[67] and it is essential for both
proliferation and activation of differentiation
pathways.[68] It has been observed that highly
proliferating malignant cells have less gap junc-
tions than the most differentiated ones.[69] In
particular, connexin 43 (Cx43) is a tumor sup-
pressor,[69] and its expression is reduced in vari-
ous tumors.[70,71] The forced expression of the
Cx43 gene in several Cx43-deficient tumor cell
lines attenuates their malignant phenotype,[72,73]
although the mechanisms by which the Cx43 gene
inhibits the tumor growth remain unclear. The
role of Cx43 alone and combined with an HDA-
CI in tumor growth inhibition has shown that
(i) trasfecting Cx43 plasmid DNA (pCMV-Cx43)
into human nasopharyngeal cancer KB cells,
using folate-linked nanoparticles, induces inhibi-
tion of cell growth (Cx43 induced a tumor sup-
pressive effect via a gap junctional intercellular
communication-independent mechanism); and
(ii) the transfection of pCMV-Cx43 along with
phenylbutyrate greatly enhances Cx43 expression
in vitro, and significantly inhibits the tumor
growth of KB cells and xenografts compared with
that of pCMV-Cx43 alone. Phenylbutyrate in-
duces an increased expression of genes of DNA
damage checkpoints and of apoptosis via the down-
regulation of anti-apoptotic b-cell lymphoma
(bcl-2)messenger RNA (mRNA) expression and up-
regulation of the activity of the apoptosis-associated
enzyme caspase-3/7.[74]
The combined treatment 50-azacytidine/
phenylbutyrate results in a partial but efficient
demethylation of the miR-203 upstream region
both in the two T-cell leukemia cell lines, KAR-
PAS-45 and PEER, and in the two Ph-positive
chronic myelogenous leukemia (CML) cell lines,
K562 and KCL-22, restoring miR-203 expres-
sion (a tumor suppressor miRNA controlling the
expression levels of ABL1, a classic oncogene
extensively characterized in hematopoietic ma-
lignancies, and the expression levels of the BCR-
ABL1 translocation protein, produced by the
Philadelphia chromosome, which is a hallmark of
CML and some B-cell leukemias in children). The
re-expression of this miRNA dramatically reduces
the proliferation of tumor cells and strongly cor-
relates with a significant reduction in both ABL1
and BCRABL1 protein levels. This fact suggests
that epigenetic drugs, in addition to re-expressing
other methylated complementaryDNAs, can result
in oncogene downregulation mediated by the
chemical restoration of miRNA function.[75]
It has been observed that phenylbutyrate
(i) induces up to 70% apoptosis in pancreatic
carcinoma cell lines Panc 1, T4M-4, COLO 357,
and BxPc3, while it leads to cell cycle arrest in
only T3M-4 and Colo357 cells, which have been
found to express p21 to a higher extent than
Panc1 and BxPc3 cells; (ii) it increases gap junc-
tion communication between adjacent T3M-4
cells in a concentration-dependent manner and
efficiently inhibits cellular export mechanisms in
pancreatic carcinoma cell lines Panc 1, T4M-4,
COLO 357, and BxPc3 cells; (iii) in combination
with gemcitabine, phenylbutyrate shows an over-
additive effect on induction of apoptosis in BxPc3
and T3M-4 cells (up to 4.5-fold compared with
single drug treatment) with accompanied activa-
tion of caspase 8, BH3 interacting domain death
agonist (Bid) and poly (ADP-ribose) polymerase
family, member 1 (PARP) cleavage; (iv) in con-
centrations exceeding 2.0mmol/L it sensitizes
H6c7 cells (a pancreatic ductal epithelial cell line
not of malignant origin, but characterized by im-
mortality and a high proliferation rate), which
suggests that phenylbutyrate does not act on ma-
lignant cells specifically, but also on other highly
proliferating immortalized cells; and (v) it does not
affect low proliferating primary human fibroblasts
and peripheral blood mononuclear cells.[76]
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A pilot study of five African patients with
Burkitt lymphoma, has shown that phenylbutyrate,
administered before cyclophosphamide, induced
shrinkage of cyclophosphamide-resistant tumors
in two patients, at least temporarily. A compar-
ison of the responses of these two patients sug-
gests that phenylbutyrate pretreatment for
6 days, before cyclophosphamide, is more effec-
tive than pretreatment for 2.5 days.[77]
It has been shown that phenylbutyrate signif-
icantly reduces the number of inclusions in glucose
oxidase and acetyl-leucyl-leucyl-norleucinal-treated
cells (human hepatoma cell line established from
a hepatocellular carcinoma [Huh7 cells] and a
highly differentiated immortalized human hepa-
tocyte cell line [OUMS-29 cells]), indicating that
endoplasmic reticulum (ER) dysfunction, in-
duced by glucose oxidase and acetyl-leucyl-leucyl-
norleucinal, influences the formation of inclusions.
These phenomena are reversed by a co-treatment
with phenylbutyrate, which, due to its properties of
chemical chaperone, reduces the ER stress.[78]
The effect of a combination treatment with
the DNA methyltransferase inhibitor 5-aza-20-
deoxycytidine (5-aza-CdR) and the HDACI
phenylbutyrate on a set of CCD-1070SK (human
normal fibroblasts) and cancer cell lines (T24
[bladder transitional carcinoma cells], CFPAC-1
[pancreatic carcinoma cells], CALU-1 [lung car-
cinoma cells], NCCIT [embryonal carcinoma
cells]) has been studied and the results have shown
that (i) low doses of the drug combination cause
cell cycle arrest, whereas high doses induce apo-
ptosis in T24 bladder carcinoma cells; (ii) both
p16 (CDKN2A/INK4) and p21 (CIP1/SDI1/
WAF1) expression is induced to similar levels
in normal and cancer cells in a dose-dependent
fashion after combination treatments; (iii) a dis-
tinct increase of histone H3 acetylation at lysine
9/14 near the transcription start sites, in both
LD419 normal fibroblasts and T24 bladder car-
cinoma cells, has been observed, and instead the
acetylation changes in the p21 locus are less ap-
parent; (iv) the levels of trimethylation of histone
H3 on lysine 9 do not change after drug treat-
ments and there is evidence that the remethylation
of the p16 promoter CpG island in T24 cells after
5-aza-CdR treatment cannot be halted by a sub-
sequent continuous phenylbutyrate treatment; and
(v) the p16 gene is resilenced with kinetics similar to
5-aza-CdR-only-treated cells, which is also marked
by a localized loss of histone acetylation at the
transcription start site.[79]
Cyclo-oxygenase-2 is frequently overexpressed
in non-small cell lung cancer (NSCLC) and results
in increased levels of prostaglandin E2, an im-
portant signaling molecule implicated in tumori-
genesis, with levels that have increased following
cyclo-oxygenase-2 overexpression in NSCLC. It
exerts its effects through the E prostanoid (EP)
receptors (EPs1–4). In NSCLC cell lines (Beas-2B
[transformed normal human bronchoepithelial],
H460 [large cell], H647 [adenosquamous carci-
noma], A549 [adenocarcinoma] and SK-MES-1
[squamous cell carcinoma]), histone acetylation
has been found to be a critical regulator of EP
expression with TSA, phenylbutyrate, and sub-
eroylanilide hydroxamic acid, as they induce in-
creased expression of EPs2–4. In addition, direct
chromatin remodeling has been demonstrated at
the promoters for EPs2–4.[80]
AML cells (cell lines K562, CMK, HL-60,
KG-1a, and SK-Hep-1) have been cultured in
the presence of phenylbutyrate, valproate, sub-
eroylanilide hydroxamic acid, or TSA and ana-
lyzed for drug transporter expression and function
as well as sensitivity to anticancer drugs. Phenyl-
butyrate has induced P-glycoprotein and breast
cancer resistance protein expression and the efflux
of drugs as determined with labeled substrates.
KG-1a cells, treated with phenylbutyrate, have de-
veloped resistance to daunorubicin, mitoxantrone,
etoposide, vinblastine, paclitaxel, topotecan, gem-
citabine, and 5-fluorouracil, resulting in an im-
pairment of drug-induced apoptosis.[81]
p21waf1/Cip1 (p21) is a tumor suppressor
gene involved in apoptosis in many cancer cell
types induced by different agents. In hepato-
cellular hepatocarcinoma, Hep3B cells trans-
fected by EGFP-p21 anti-sense or sense plasmids,
apoptosis induced by phenylbutyrate, and TSA
has been assessed by terminal transferase dUTP
nick end labeling (TUNEL) assay. The results have
shown that the p21 anti-sense construct prevents
apoptosis induced by HDACIs in Hep3B cells.
The obtained results suggest an important role
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for p21 in mediating the apoptotic effect of
HDACIs.[82]
An experimental study has investigated the
antineoplastic effect of TSA and phenylbutyrate
on the human glioblastoma cell lines GBM-29,
U-343 MG, and U-343 MGa Cl. 2 : 6, giving the
following results: (i) TSA and phenylbutyrate
have induced apoptosis in the three cell lines in a
dose- and time-dependent manner, and caspase-3
activation has been detected in all three cell lines;
(ii) U-343 MG cells have been more sensitive to
the apoptotic effect of HDACI compared with
U-343 MGa Cl. 2 : 6; (iii) TSA and phenylbutyrate
have induced differentiation in the three cell lines,
each cell line developing unique phenotypic
characteristics; (iv) during long-term treatment
with a low dose of HDACI U-343 MGa Cl. 2 : 6
cells have developed an astrocytic morphology
with expression of glial fibrillary acidic protein
(GFAP); (v) GFAP-negative U-343 MG cells
have changed their morphology in response to
HDACI and downregulated their expression of
vimentin; and (vi) the nestin and vimentin pos-
itive GBM-29 cells have also shown a morpho-
logic differentiation, while the expression of the
two malignancy markers has decreased.[22]
Treatment of tumor cells (human prostate
[PC3, DU-145 (ATCC)] and colon carcinoma cell
lines [HCT116,HCT116 p21¡/¡, HCT116 p53¡/¡])
with phenylbutyrate and 13-cis-retinoic acid
(CRA) and with paclitaxel and doxorubicin has
been studied with the following results: (i) in-
hibition of tumor cell growth has been greatly
enhanced when compared with phenylbutyrate
+CRA, paclitaxel or doxorubicin alone, with
>90% growth inhibition; (ii) when the cells have
been pretreated with phenylbutyrate +CRA, fol-
lowed by paclitaxel or doxorubicin, the enhanced
inhibition is abolished; (iii) treatment with phe-
nylbutyrate +CRA restores sensitivity to doxo-
rubicin in the PC-3 human prostate cancer cell
line; (iv) phenylbutyrate +CRA induces p21 ex-
pression and cell cycle arrest in the G1 phase,
while paclitaxel and doxorubicin induce G2/M
arrest; (v) p21- and p53-deficient colon carcino-
ma cell lines are more sensitive to the effect of
phenylbutyrate +CRA and paclitaxel as single
agents and in combination, compared with the
wild-type cells; (vi) when the p21-deficient cells
are pretreated with phenylbutyrate +CRA, fol-
lowed by paclitaxel, the protective effect is still
observed; (vii) treatment of tumor cells with a
combination of these drugs induces cell cycle
delay at multiple mitotic checkpoints before un-
dergoing apoptosis; (viii) the tumor growth is sig-
nificantly inhibited and delayed in male athymic
nude or female BALBc mice treated with either
paclitaxel or concomitantly with paclitaxel and
phenylbutyrate +CRA compared with control;
and (ix) animals, treated with all three agents,
demonstrate further growth inhibition or delay
compared with the paclitaxel alone or phenyl-
butyrate +CRA arm.[83]
It has been suggested that phenylbutyrate can
produce p21-independent cytostasis, and en-
hance radiation sensitivity in p53 mutant human
glioblastoma cells in vitro (D54, U87-MG, U251,
and SKMG-3), suggesting the potential applica-
tion of combined phenylbutyrate and radiother-
apy in glioblastoma harboring mutant p53.[84]
An experimental study has shown that treat-
ment of different metastatic melanoma cell lines
(SK-Mel-19, SK-Mel-29, and SK-Mel-147 mela-
noma cells; 1.5 · 106) with 5-azacytidine-CdR, a
potent inhibitor of cytosine methylation, sig-
nificantly induces 14-3-3s protein expression1
and additional treatment with phenylbutyrate
further enhances 14-3-3s expression. The induc-
tion of 14-3-3s expression by 5-azacytidine-CdR/
phenylbutyrate treatment leads to almost com-
plete inhibition of cell proliferation, with cells
predominantly arrested in G2-M. The antiprolif-
erative effect of 5-azacytidine-CdR/phenylbutyrate
is reversed in 14-3-3s knockdown cells.[85]
A 6-hour pretreatment with phenylbutyrate and
vitamin B3 on human promyelocytic leukemia cells
HL-60, before the exposition to all-trans-retinoic
acid (RA) alone or in combination with vitamin B3,
1 14-3-3 proteins play an important role in cancer biology by interfering with intracellular signaling pathways
and cell cycle checkpoints, and in particular the 14-3-3s isoform acts as a tumor suppressor and is often in-
activated during the tumor development.
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has shown a significant acceleration and high level of
granulocytic differentiation. The effects are asso-
ciated with a rapid histone H4 acetylation and later
histone H3 modifications.[86] It is important to un-
derline that vitamin B3 inhibits sirtuins, NAD
+-
dependent protein deacetylases that are involved in
transcriptional regulation, metabolism, apoptosis,
differentiation, and aging.[87]
Phenylbutyrate, at different concentrations,
has been used to treat hepatocellular carcinoma
cells Bel-7402 and normal liver cell line L-02
showing: (i) a time-dependent growth inhibition
in hepatocellular carcinoma cells Bel-7402; (ii) a
significant decline in the fraction of S phase cells
and significant increase in G0/G1 cells; (iii) an
increase in the expression of P21WAF1/CIP1 and
E-cadherin in Bel-7402 and a significant decrease
in the level of HDAC4 in Bel-7402; (iv) a signif-
icant improvement in the level of acetylating
histone H4; (v) no distinct changes in the normal
liver cell line L-02 suggesting phenylbutyrate to
be safe for clinical treatment; (vi) the inhibition
in the growth of hepatocellular carcinoma cells
Bel-7402 and induction of partial differentiation
through the enhancement of the acetylating his-
tones; and (vii) no significant effect on normal
liver cells have been observed. These results un-
derline the safety of phenylbutyrate, emphasizing
that it may have great potential as a growth in-
hibitor for hepatocellular carcinoma.[88]
The clinical trials involving the use of phenyl-
butyrate for treatment of cancer are summarized
in table SI (Supplemental Digital Content 1,
http://links.adisonline.com/DRZ/A3).
4. Motor Neuron Disorders
Motor neuron diseases are a group of fatal
neurologic progressive disorders, and the most
common are spinal muscular atrophy (SMA) and
amyotrophic lateral sclerosis (ALS), both char-
acterized by the loss of spinal motor neurons. No
effective cure exists, but there have been major
advances to understand the molecular and ge-
netic mechanisms involved in these pathologies.
Riluzole stops the advance of the disease by
blocking the effects of the neurotransmitter glu-
tamate and it is thought to extend the lifespan of
ALS patients for few months.[89] In particular,
the use of phenylbutyrate and its derivatives has
been widely investigated both in vitro and in vivo.
Important genes, playing a key role in motor
neuron diseases, have been discovered during the
past few years and several pathways have been
recently implicated in these pathologies, i.e.
pathways that affect RNA processing, axonal
transport, and mitochondrial function.[90]
4.1 Phenylbutyrate and Spinal
Muscular Atrophy
SMA is the term for a number of conditions
characterized by the degeneration of a-motor
neurons in the brainstem and spinal cord leading
to hypotonia and muscle weakness.[91] SMA is an
autosomal recessive disease and the leading cause
of infant deaths caused by the gene survival
motor neuron 1 (SMN1).[92] SMA has been sub-
divided into three clinical groups, based on the
age of the onset of symptoms and the achieve-
ment of motor milestones, and that are due to
homozygous loss of the functional motor neuron
gene (SMN1) on chromosome 5q13. The age of
the onset in patients with SMA I is less than
6 months and these patients never acquire the
ability to sit unsupported. The onset of SMA II is
usually between 6 and 18 months and the patients
are able to sit unsupported, but are not able to
walk. The onset of SMA III is usually >18months
and the patients are able to walk independently.[93]
The fact that SMN genes have a unique organi-
zation has led to investigation of how to make
SMN2, a gene existing in all patients, function
like the missing SMN1 gene.[92] Histone acetyla-
tion leads to DNA relaxation, making it acces-
sible to the transcriptional machinery, and its
inhibition might enhance the expression in about
2% of human genes.[94] Phenylbutyrate, the first
HDACI, found to enhance SMN2 expression,
increases exon seven inclusion in lymphoid cell
lines derived from patients with SMA. However,
its half-life of about 6 minutes in human serum
has made it impossible to develop a clinical use
for this compound.[92] Andreassi et al.[95] reported
that phenylbutyrate treatment caused an increase
in full-length SMN2 transcripts in fibroblast cell
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cultures from 16 SMA patients and it is was also
effective in enhancing SMN protein levels and the
number of SMN-containing nuclear gems. There-
fore, this compound could represent a valuable
candidate for pharmacologic treatment of SMA.[95]
It has been shown that the SMN2 gene is subject
to gene silencing by DNA methylation, which
might have major implications for SMA disease
progression and upcoming pharmacologic inter-
ventions for epigenetic SMA therapy.[96]
It has been found that treatment of SMA-like
transgenic mice with the hyperacetylating agent
phenylbutyrate effectively increases the expres-
sion of SMN protein in motor neurons of the
spinal cord,[97] and phenylbutyrate significantly
increases SMN expression in fibroblast cultures
from SMA patients.[95]
It has been shown that five pan-HDACIs, in-
cluding SAHA, as well as the cyclic tetrapeptide
romidepsin (FK-228), are able to bypass LT-SMN2
gene silencing in SMA fibroblasts and human
hippocampal brain slice cultures (OHSCs), re-
sulting in up to 5-fold inductions of total SMN2
transcript levels. In contrast, the HDAC iso-
enzyme selective inhibitors MS-275, VPA, and
phenylbutyrate display only moderate effects,
suggesting that pan-HDACIs possess superior
functional capacities to activate SMN2. Among
the pan-HDACIs, vorinostat appears to be promis-
ing, as this molecule has been shown to cross the
blood-brain barrier. Moreover, ongoing clinical
research in cancer patients has shown a good oral
bioavailability and biologic activity.[96] The clin-
ical trials involving the use of phenylbutyrate for
treatment of SMA are summarized in table SII
(see Supplemental Digital Content).
4.2 Phenylbutyrate and Amyotrophic
Lateral Sclerosis
ALS is a fatal neurodegenerative disorder,
characterized by a loss of upper and lower motor
neurons in the brain and spinal cord, and leading
to a progressive muscle wasting and limb paral-
ysis, dysphagia, dysarthria, and respiratory fail-
ure.[98,99] About 10% of patients report a family
history, and mutations in SOD1 (which encodes
superoxide dismutase-1) are the cause in about
20% of these cases; 3% and 4% of familial cases,
respectively, have been related to TARDBP (also
known as TDP-43, which encodes TAR DNA-
binding protein) and FUS (RNA-binding protein
fusion), which have been linked to familial forms
of the disease. Sporadic ALS has been associated
with another gene, ELP3 (elongator protein 3),
which encodes the catalytic subunit of the HAT
complex elongator protein 3. ALS also features
cytoplasmic deposits of misfolded proteins, con-
sisting of SOD1, TARDBP, or FUS aggregates.[100]
Riluzole (anFDA-approvedALS therapy) provides
a 2- to 3-month prolongation of survival.[101,102] To
date, no other drug therapies have been shown to
slow or abrogate the disease process in ALS. It has
been reported that the mean survival of patients
from the onset of symptoms is 3–5 years.[103] The
different types of ALS pathologies are studied in
transgenic rodent models of ALS, expressing
mutant forms of SOD1.[104] Mice, overexpressing
a human SOD1 mutation, are characterized by a
glycine, which is substituted by an alanine at amino
acid position 93[105] since these transgenic models
develop clinical and pathologic features that are
similar to those in human diseases.[105-107] Ap-
optotic cell death is a common cellular event in
both animal models and patients with ALS,[108]
as suggested by the observations that increased
expression of bcl-2, the dominant negative inhi-
bition of caspase-1, and the administration of tetra-
peptide caspase inhibitors delay the onset of the
disease and prolong survival in ALS mice.[109-111]
Neuroprotective therapies that target specific
neurotoxic molecular mechanisms in ALS mice
have the potential to delay the onset and slow the
progression of the disease in ALS, and phenyl-
butyrate has been proposed as a good candidate
for this kind of therapy.
Pharmacologic treatment, using phenylbutyrate
(the animals received either 200, 400, 600, or
800mg/kg intraperitoneally or phosphate-buffered
saline [PBS] injection, i.e vehicle; treatment was
started at 21 and 70 days, before and after the
occurrence of the symptoms), significantly ex-
tends survival and improves both the clinical and
neuropathologic phenotypes in G93A transgenic
ALS mice. Moreover, it ameliorates histone hy-
poacetylation and induces expression of nuclear
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factor-kB (NF-kB) p50, the phosphorylated in-
hibitory subunit of NF-kB (pIkB) and bcl-2, and
it reduces cytochrome c and caspase expres-
sion. The same authors propose that the pharma-
cologic induction ofNF-kB-dependent transcription
and bcl-2 gene expression is neuroprotective in
ALS mice by inhibiting programmed cell death,
in particular: (i) phenylbutyrate acts to phos-
phorylate pIkB, translocating NF-kB p50 to
the nucleus, or to directly acetylate NF-kB p50;
(ii) NF-kB p50 transactivates bcl-2 gene expres-
sion; and (iii) upregulated bcl-2 blocks cytochrome
c release and subsequent caspase activation, slow-
ing motor neuron death. These transcriptional and
post-translational pathways ultimately promote
motor neuron survival and ameliorate disease pro-
gression in ALS mice.[38]
The catalytic antioxidant Mn (III) porphyrin
AEOL 10150 (2.5mg/kg/day; systemic administra-
tion), phenylbutyrate (400mg/kg/day; intraperi-
toneal administration) and the combination of
phenylbutyrate and AEOL 10150 have been tested
in G93A transgenic familial ALS mice (admin-
istered from the onset of the disease, i.e. after the
appearance of motor dysfunction) observing that
(i) AEOL 10 150 alone improved motor function
and extended survival by 11%; (ii) phenylbutyrate
alone significantly improved motor function and
extended survival by 13%; and (iii) phenylbutyrate
and AEOL 10 150 together increased survival by
19%. An increase in histone acetylation was con-
firmed by Western blot and quantitative real-
time PCR analysis revealed the upregulation of
the compounds capable of protecting cells against
oxidative stress and apoptosis. Markers of oxi-
dative damage were reduced in the lumbar spinal
cord when compared with vehicle administration.
This study suggests that agents inhibiting apop-
tosis and blocking oxidative stress show efficacy
in treating mutant-SOD1-associated ALS and that
a combination of agents, targeting different dis-
ease mechanisms, may exert additive therapeutic
effects.[112]
The combined treatment of riluzole and phe-
nylbutyrate significantly extends survival and
improves both clinical and neuropathologic phe-
notypes in G93A transgenic ALS mice. In partic-
ular, the combination therapy increased survival
by 21.5%, compared with the separate administra-
tion of riluzole (7.5%) and phenylbutyrate (12.8%),
while improving both bodyweight loss and grip
strength. Riluzole/phenylbutyrate treatment ame-
liorates gross lumbar and ventral horn atrophy,
attenuates lumbar ventral horn neuronal cell
death, and decreases reactive astrogliosis. In ad-
dition, riluzole/phenylbutyrate administration
increases acetylation at H4 and increases NF-kB
p50 translocation to the nucleus in G93A mice.[113]
An open-label study, involving 40 patients
with ALS, has been performed to establish the
safety and pharmacodynamics of escalating dos-
ages of phenylbutyrate in 26 participants who
completed a 20-week treatment phase. It showed
that phenylbutyrate is safe and the majority of
subjects tolerated higher dosages (21 g/day) of
this drug, but the lowest dose (9 g/day) was ther-
apeutically efficient in improving histone acety-
lation levels. No deaths or clinically relevant
laboratory changes occurred with phenylbutyrate
treatment. Histone acetylation decreased by ap-
proximately 50% in blood buffy-coat specimens
at screening and significantly increased after phe-
nylbutyrate administration. In addition, blood lev-
els of phenylbutyrate and the primary metabolite
(PAA) increased with dosage.[114]
4.3 Phenylbutyrate and Ischemia
Retinal ischemia is a common cause of visual
impairment for humans and animals. Retinal is-
chemia has been typically observed as a con-
sequence of the presence of diabetic retinopathy,
glaucoma, and retinal-artery occlusion.[115] Is-
chemic retinal injury consists of a self-reinforcing
cascade of destruction involving neuronal depo-
larization, calcium influx, and oxidative stress
initiated because of energy failure, and increased
glutamatergic stimulation.[116,117]
A study has investigated the neuroprotective
effects of phenylbutyrate upon retinal ischemic
injury using Sprague Dawley rats. Retinal gan-
glion cells (RGCs) were retrograde labeled with
the fluorescent tracer fluorogold applied to the
superior collicoli of test Sprague Dawley rats and,
7 days after that, high intraocular pressure and
retinal ischemiawere induced. The animals received
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either 100 or 400mg/kg PBA intraperitoneally,
30 minutes prior to the induction of retinal is-
chemia and 1 hour subsequent to the cessation of
the procedure inducing retinal ischemia. Histo-
logic analysis has revealed that ischemic injury
causes the loss of retinal RGCs and a net decrease
in retinal thickness. Moreover, it has been ob-
served that in the phenylbutyrate-treated groups,
almost 100% of the RGCs have been preserved by
a pre-ischemia treatment with phenylbutyrate (at
a dose of either 100 or 400mg/kg), while post-
ischemia treatment of RGCs with phenylbutyrate
has not led to the preservation of RGCs from
ischemic injury by phenylbutyrate, as determined
by the counting of whole-mount retinas. Pre-
ischemia treatment of RGCs with phenylbutyrate
(at a dose of either 100 or 400mg/kg) has signif-
icantly reduced the level of ischemia-associated
loss of thickness of the total retina, especially the
inner retina and the inner plexiform layer of ret-
ina. Besides, phenylbutyrate treatment has sig-
nificantly reduced the ischemia-induced loss of
cells in the ganglion-cell layer of the retina.[118]
It has been observed that, if we target the ER by
administration of intraperitoneal phenylbutyrate
(1 hour before and 12 hours after reperfusion)
the liver is protected against ischemia/reperfusion
injury in male C57BL/6 mice subjected to warm
ischemia (70% of the liver mass, 45 minutes), as
evidenced by the decreased liver enzymes and re-
duction in the number of non-viable cells and
PMN infiltrates into the liver. Moreover, the
hepatoprotective properties of phenylbutyrate
have further been demonstrated by a reduction in
apoptosis after reperfusion. This study shows that
phenylbutyrate reduces mortality in a lethal model
of total ischemia/reperfusion injury to the liver (all
vehicle-treated controls died within 3 days after
reperfusion while 50% survival [>30 days] has been
observed in animals given phenylbutyrate).[119]
4.4 Phenylbutyrate and Urea Cycle Disorders
The urea cycle is the final common pathway
for the excretion of waste nitrogen in mammals,
and the defects in this cycle, observed in the neo-
natal period, are usually associated with severe
and rapidly worsening hyperammonemia which,
if not treated, leads to cerebral and pulmonary
hemorrage, leaving the baby severely handicapped
or leading to death.[120] It has been reported that
all the UCDs are associated with an accumulation
of glutamine and alanine, and are characterized
by a difficult diagnosis since they are associated
with nonspecific symptoms such as poor feeding,
vomiting, lethargy and/or irritability, and tachy-
pnea. These babies can show a transient respi-
ratory alkalosis, neuromuscular irritability and
stridor, which are only transient, with the patients
deteriorating rapidly, becoming unresponsive,
and requiring intensive care. Other complications
are changes of tone, with loss of normal reflexes,
vasomotor instability and hypothermia, apnoea
and fits, while a disordered liver function could be
a secondary complication. Measurement of plas-
ma ammonia concentration is the main diagnostic
test for the UCD (plasma ammonia, in healthy
neonates, is normally <65mmol/L,[121] and reaches
180mmol/L in sick neonates; it is >200mmol/L in
patients with inborn errors and achieves higher
levels in patients with UCD).[120]
In cases of significant hyperammonemia, the
following investigations could be useful: blood
pH and gases, plasma urea and creatinine, elec-
trolytes, glucose, liver function tests and clotting
studies, plasma amino acids, urine organic acids,
orotic acid and amino acids, and plasma free and
acylcarnitines.[120] The therapy for this disease is
directed at decreasing the requirement for urea
biosynthesis by decreasing dietary nitrogen in-
take and increasing waste nitrogen excretion. It
is achieved by prescribing phenylbutyrate, a pre-
cursor of PAA that conjugates with glutamine
to yield phenylacetylglutamine, a waste nitrogen
compound that is rapidly excreted in the urine.[122]
The use of phenylbutyrate to treat UCD is due
to its ability to be oxidized in the liver to PAA,
which is then conjugated with glutamine, result-
ing in phenylacetylglutamine, which is excreted in
the urine and hence 2mol of nitrogen is lost for
each mole of the given phenylbutyrate.[123] An
early diagnosis is fundamental because the prog-
nosis often depends on urgent treatment. Family
investigation and genetic counseling play a pre-
ventive key role. When elevated plasma ammonia
levels are found, a low-protein diet, with supple-
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mental arginine, and with both sodium benzoate
and phenylbutyrate to remove excess nitrogen,
has been suggested as treatment.[124]
Three cases of patients with hyperammonemia
who received accidental inappropriate doses of
intravenous sodium benzoate and PAA that have
resulted in severe complications have been reported.
All the patients showed alteration in mental sta-
tus, Kussmaul respiration, and a partially com-
pensated metabolic acidosis with an increased
anion gap. Two patients developed cerebral edema
and hypotension, and died; the third patient sur-
vived after hemodialysis, and plasma levels of
benzoate and PAA were excessively high in all of
them.[125] During pregnancy, benzoate might be
the best choice because it is usually ingested with
soft drinks and several types of food, while phe-
nylbutyrate can affect many metabolic and other
functions. Phenylbutyrate tablets are considered
to be dangerous because they can cause serious
tissue damage in the esophagus, underlining the
importance of instructions to the patient to en-
sure correct swallowing of the drug.[126]
OTC deficiency is the most common urea cycle
defect, usually affecting males in the neonatal
period and causing acute hyperammonemic coma
and leading to death if not treated.[124] OTC is an
x-linked mitochondrial enzyme that catalyzes the
synthesis of citrulline from carbamoyl phosphate
and ornithine. A deficiency in this enzyme leads to
hyperammonemia and hyperglutaminemia, hy-
poargininemia, hypocitrullinemia, and episodic
encephalopathy that, if uncontrolled, results in
brain injury and death. In boys, the disease is
often fatal when its onset occurs during the neo-
natal period, but it is milder when the onset oc-
curs later in childhood. Heterozygous girls may be
normal or may have episodes of hyperammonemic
encephalopathy and decline in cognitive func-
tion.[19] This condition has also been observed
in the later childhood (between 15 months and
5 years) and has been often under-recognized.[127,128]
This pathology is characterized, in the neonatal
period, by feeding difficulties, lethargy, respiratory
distress, impairment of consciousness, vomiting,
convulsions, and coma. In later life the most im-
portant symptoms that might occur are headache,
vomiting, lethargy, hyperventilation, episodes of
abnormal behavior, and sometimes disorienta-
tion and confusion, ataxia, hypotonia, and focal
neurologic signs such as hemiplegia[128] (proposed
to be due to alterations in vascular endothelial
wall integrity or alterations in cerebral perfusion
and metabolism with an accumulation of toxic
metabolites).[129] Cases of acrodermatitis and
enteropathica-like rashes have been reported,
probably associated with a deficiency of arginine,
an amino acid that represents the 16% of the
amino acid content of the human epidermal ker-
atin.[130] The voluntary adoption of a vegetarian
diet has been observed.[131] Acute pancreatitis has
also been reported as a complication.[132] The
clinical trials, involving the use of phenylbutyrate
for treatment of UCD, are summarized in table
SIII (see Supplemental Digital Content).
4.5 Sickle Cell Disease and Thalassemias
b-Thalassemia is an autosomal recessive genetic
disease, caused by variations in the inactivation
mechanism of the b-globin genes,[133] that shows
clinical symptoms ranging from mild symptom-
less anemia to transfusion dependence. No ad-
equate treatment for the various phenotypes has
been established yet. The current management of
this condition includes the use of regular red
blood cell transfusions and iron chelation ther-
apy. Bone marrow transplantation could be an
important therapeutic choice, although it is not
an option for the majority of the patients. The
development of an effective therapy to increase
hemoglobin levels in homozygous b-thalassemia,
without the use of red blood cell transfusions,
could allow normal growth and development
while decreasing or eliminating transfusional iron
overload, which is the leading life-threatening
factor in patients with this disease.[134] Butyrate
analogs are able to induce erythroid differentia-
tion[135-137] and stimulate hemoglobin F production
in human erythroid progenitors in vitro.[138-140]
In vivo, they reactivate embryonic globin pro-
duction in an avian model,[141] delay the switch
from fetal to adult globin in ovine fetuses,[142] and
increase fetal hemoglobin (HbF) production in
adult primates.[140,143-145] In humans, phenyl-
butyrate is able to stimulate fetal hemoglobin
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production.[146,147] For themajority of children with
b-hemoglobinopathies and b-thalassemias who do
not have a transplant donor, survival is shortened
and morbidity is high. Hydroxyurea, recombinant
human erythropoietin preparations, phenylbutyrate,
arginine butyrate, and 5-azacytidine/decitabine have
shown efficacy in approximately 40–70% of sickle
cell and b-thalassemia patients.[148]
The clinical trials involving the use of phenyl-
butyrate for treatment of sickle cell disease and
thalassemias are summarized in table SIV (see
Supplemental Digital Content).
4.6 Phenylbutyrate and Cystic Fibrosis
Cystic fibrosis (CF) is an autosomal recessive
disorder caused by mutations in the CF trans-
membrane conductance regulator (CFTR) gene.[149]
The DF508 mutation is caused by a three base
pair deletion in the gene for CFTR, resulting in
the loss of a phenylalanine residue at position 508
in the CFTR protein and this mutation fails to
fold properly in the ER, which leads to ubiquiti-
nation and degradation of the protein in the
proteasome.[150,151] The DF508-CFTR protein,
which is retained in the ER and degraded rather
than trafficked to the cell surface, forms a func-
tional chloride channel in reconstituted bilayers,
but with decreased mean open times, and there-
fore decreased conductance compared with wild-
type CFTR. This fact underlines how treatments
that would promote DF508-CFTR trafficking
beyond the ER might restore partial CFTR
chloride channel function at the cell surface.[152]
Two members of the 70kDa heat shock protein
family, HSP70 and HSC70, interact with CFTR,
and the regulation of these heat shock protein-
CFTR interactions can restore DF508-CFTR traf-
ficking as shown in a study proving phenylbutyrate
modulates heat shock protein function and restores
DF508 maturation in vitro and in vivo.[15] Heat
shock proteins are constitutive and stress-inducible
proteins that can protect normal cells against pro-
tein damage by physical interaction during syn-
thesis, folding, assembly, and degradation.[153]
In cultured cells, the deregulation of DF508-
CFTRbybutyrate has been observed.[154]Moreover,
phenylbutyrate, at micromolar concentrations,
induces CFTR channel function on the plas-
mamembrane of DF508-expressing CF airway epi-
thelial cells (in IB3-1 cells [an immortalized CF
cell line containing the mutations DF508 and
W1282X]) in vitro.[155] CFTR mutations have
been categorized into five major classes: (i) the
total absence of CFTR (class I); (ii) defects in
CFTR folding and trafficking, leading to reduced
amounts of mature CFTR (class II; the DF508 is
the prototype class II trafficking mutation and
has been found in >70% of patients with CF);
(iii) abnormal regulation of chloride conduc-
tion in an otherwise mature CFTR (class III);
(iv) decreased chloride conduction in a fully pro-
cessed CFTR (class IV); and (v) decreased CFTR
synthesis (class V).[156]
A study investigating the effects of genistein
and phenylbutyrate on CFTR in three human
airway epithelial cell lines expressing wild-type or
DF508 CFTR (Calu-3, CFSMEo-, and CFBE41o-
cells) loaded with the fluorescent dye N-(ethoxy-
carbonylmethyl)-6-methoxyquinolinium bromide
to study the chloride efflux, has shown that
(i) forskolin and 3-isobutyl-1-methylxanthine
(IBMX) induce chloride efflux in Calu-3 cells but
not in CF lines; (ii) genistein (2.5–50 mmol/L) is
able to induce chloride efflux in all cell lines but
does not enhance the effect of forskolin and
IBMX; and (iii) phenylbutyrate has little or no
effect on genistein-induced chloride efflux.[157]
A study has investigated the ability of phe-
nylbutyrate, genistein, and 8-cyclopentyl-1,3-
dipropylxanthine (CPX) to activate the defective
chloride channel in the CF bronchial epithelial
cell line CFBE41o-, which expresses the DF508
mutation. It was investigated through x-ray micro-
analysis. Both genistein and CPX act by stimulating
the chlorine flow end increasing the transmem-
brane conductance in CF. It was observed that
8-bromo-cyclic-adenosine monophosphate (cAMP)
alone does not induce Cl- efflux in CFBE41o-
cells, but, after incubation with phenylbutyrate, a
significant efflux of Cl- occurs showing that
phenylbutyrate allows the DF508 CF transmem-
brane conductance regulator to escape degrada-
tion and to be transported to the cell surface. The
stimulation of cells, with a combination of genis-
tein and cAMP, also induces Cl- efflux, whereas
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a combination of pretreatment with phenyl-
butyrate and a combined stimulation with genis-
tein and cAMP induces an even larger Cl- efflux.
Cl- efflux could also be stimulated by CPX, but
this effect is not enhanced by phenylbutyrate
pretreatment.[158]
It has been shown that arginine butyrate (AB)
and two novel short-chain fatty acid derivatives,
a-methylhydrocinnamic acid (ST7) and 2,2-
dimethyl-butyrate (ST-20), functionally correct
the DF508-CFTR defect in airway IB3-1 cells,
which are heterozygotes for the CFTRmutations
DF508 and W1282X.[159]
Singh et al.[160] have highlighted a specific subset
of HSP70 system proteins that sense the rescue of
DF508-CFTR from ER-associated degradation
(ERAD). The phenylbutyrate-mediated rescue of
DF508-CFTR is associated with changes in the
network of ER-resident cytosolic chaperones and
proinflammatory responses that mimic patterns
of protein interaction observed with wild-type
CFTR expression.
The proteome profiling of IB3-1 CF bronchial
epithelial cells, treated with phenylbutyrate, has
been investigated to identify butyrate-responsive
cellular chaperones, protein-processing enzymes,
and cell-trafficking molecules associated with the
amelioration of the chloride transport defect in
these cells (analyzed by two-dimensional gel elec-
trophoresis and mass spectrometry). The same
study has shown that over a pI range of 4–7 and
molecular weight 20–150 kDa, a total of 85 dif-
ferentially expressed proteins have beem detected.
They were mostly chaperones, catalytic enzymes,
and proteins comprising structural elements, cel-
lular defense, protein biosynthesis, trafficking
activity, and ion transport.[161]
Phenylbutyrate decreases the expression of
HSC70 mRNA and protein by inducing cellular
adaptations that result in the decreased stability
of HSC70 mRNA. Phenylbutyrate has been ob-
served to stimulate the degradation of HSC70
mRNA in IB3-1 cells without significantly alter-
ing HSC70 mRNA synthesis, promoter activity,
or protein turnover. The authors suggest that,
since this response requires a preincubation with
phenylbutyrate, it results from a cellular adapta-
tion to phenylbutyrate treatment.[162]
In an in vitro experiment, IB3-1 cells (CF epi-
thelial cells genotype; DF508/W1282X) have been
treated with phenylbutyrate 0.05–5mmol/L for
2 days in culture showing a dose-dependent re-
duction in Hsc70 protein immunoreactivity and
mRNA levels. Immunoprecipitation with Hsc70-
specific antiserum demonstrates that Hsc70 and
CFTR are associated under control conditions.
Levels of immunoreactive Hsp40, Hdj2, Hsp70,
Hsp90, and calnexin were unaffected by phenyl-
butyrate treatment. This study suggests that phe-
nylbutyrate may improve DF508-CFTR trafficking
by allowing a greater proportion of mutant CFTR
to escape association with Hsc70.[163]
Butyrate and phenylbutyrate, using patch clamp
recording from CFTR-transfected mammalian
cell lines, cause a voltage-dependent block of
CFTR Cl- currents when applied to the cyto-
plasmic face of membrane patches, with appar-
ent dissociation constants (Kds) [at 0mV] of
29.6mmol/L for butyrate and 6.6mmol/L for
phenylbutyrate. At the single channel level, both
these fatty acids cause an apparent reduction in
CFTR current amplitude, suggesting a kinetically
fast blocking mechanism. The concentration-
dependence of the block suggests that CFTR-
mediated Cl- currents in vivo may be affected by
both phenylbutyrate, used in the treatment of var-
ious diseases, including CF, and by butyrate pro-
duced endogenously within the colonic lumen.[164]
It has been proposed that a combination of
chronic treatment with phenylbutyrate or selected
flavonoids, followed by acute flavonoid ex-
posure, may be beneficial in CF as proved by an
increase in Cl- conductance measured by Cl- ef-
flux in cells (IB3-1 cells [F508/W1282X]) that are
treated for 24 hours with phenylbutyrate and
then assayed with forskolin and genistein 1mmol/L
or 5mmol/L, and also with cells treated for 24 hours
with either phenylbutyrate, apigenin 5mmol/L, or
quercetin 1mmol/L.[153]
Phenylbutyrate (5mmol/L for 6 hours) increases
the functional expression of epithelial sodium
channels (ENaCs) in the apical membrane of
non-CF and CF nasal epithelial cells by enhanc-
ing exocytosis of ENaC subunits likely via regu-
lation of heat shock proteins, suggesting that
(i) in non-CF patients, phenylbutyrate treatment
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may be useful to treat airway diseases in which
ENaC trafficking may be disrupted, as it has been
observed during hypoxia or endotoxemia; and
(ii) in CF disease, although phenylbutyrate may
be useful to restore functional mutant CFTR at
the apical membrane, it is important to keep in
mind that this effect may be counteracted by an
increase in sodium hyperabsorption.[165]
The clinical trials involving the use of phenyl-
butyrate for treatment of cystic fibrosis are sum-
marized in table SV (see Supplemental Digital
Content).
4.7 Phenylbutyrate and Huntington Disease
The symptomatic Huntington disease (HD)
onset occurs typically between 30 and 50 years of
age, and mutant huntingtin has been shown to
disrupt activator-dependent transcription in the
early stages of HD pathogenesis, which has been
related to transcriptional deregulation and func-
tional loss of transcriptional co-activator proteins,
leading to neuronal loss and gliosis, particularly
in the cortex and basal ganglia regions of the HD
patient’s brain.[166] HD is an inherited autosomal
dominant neurodegenerative disorder caused by
the expansion of the polyglutamine tract near the
amino terminus of the huntington protein (HTT;
CAG trinucleotide repeat located in the Hun-
tington gene), leading to polyglutamine-dependent
inclusions, which have been seen in someHDbrains,
and some mouse models that express a small
fragment of mutant huntingtin.[167] This disease
leads to the loss of medium spiny neurons affecting
mainly the striatum (caudate nucleus, putamen,
and globus pallidus), and also the frontal and
temporal cortex causing chorea, psychiatric dis-
turbances, and cognitive impairments.[168] There
is evidence that mutant HTT interacts with the
transcription factors, leading to reduced histone
acetylation.[169] In particular phenylbutyrate im-
proves survival and attenuates striatal atrophy in
the R6/2 transgenic mouse HD model, when ad-
ministered presymptomatically, starting at 21 days
of age.[170]
Administration of the histone deacetylase
inhibitor phenylbutyrate (intraperitoneal injec-
tions of phenylbutyrate [100mL/kg/day, volume
3.33mL/kg] or vehicle [PBS, 3.33mL/kg], 6 days
per week from 75 days of age) after the onset of
symptoms in a transgenic mouse HD model
(transgenic N171-82Q mice maintained on a
B6C3F1 background) has shown that (i) a signif-
icant attenuation of gross brain atrophy and
ventricular enlargement, as well as a neuronal
atrophy after phenylbutyrate treatment (significant
at 120 days) has been observed; (ii) phenylbutyrate
treatment significantly reduces striatal neuron
atrophy in N171-82Q mice; (iii) the administra-
tion of phenylbutyrate for 2 weeks increases im-
munostaining for both acetylated histone H3 and
histone H4 in striatal neurons, and the adminis-
tration of phenylbutyrate at 100mg/kg increases
histone acetylation in the spleen and brain at
2 hours post-administration; (iv) the immuno-
cytochemistry shows a marked increase in meth-
ylation of histone 3 in the striatum at 120 days of
age, which is markedly attenuated by phenyl-
butyrate treatment; (v) the expression of selected
genes (Gfer, Gstm3, and Psma3) is significantly
upregulated after phenylbutyrate treatment
compared with controls, whereas the other genes
(Casp9, Cflar, and Prkce), after phenylbutyrate
treatment, have shown a significantly lower ex-
pression; and (vi) the caspase 3 immunoactivity
(caspase 9 is involved in activation of caspase 3,
and has increased in HD patients) at 120 days of
age is markedly increased in the striatum of the
N171-82Q mice compared with controls, and the
increase is markedly attenuated by phenyl-
butyrate treatment.[169]
Affymetrix GeneChip U133A and Amersham
Biosciences CodeLink (Amersham Biosciences)
oligonucleotide microarrays have been used to
analyze global gene expression changes in blood
samples from 17 HD subjects (12 symptomatic
and five late presymptomatic carriers of the HD
mutation) and 14 healthy, age- and gender-matched
control subjects. 322mRNAs, showing significantly
altered expression in HD blood samples, have been
identified in this study. Some changes in blood
mRNAs that clearly distinguish HD patients from
controls, and that correlate with disease progression
and response to experimental treatment, have
also been identified as follows: (i) a subset of up-
regulated mRNAs, selected from this group, is
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able to distinguish controls, presymptomatic in-
dividuals carrying the HD mutation, and symp-
tomatic HD patients; (ii) early presymptomatic
subjects have shown gene expression profiles sim-
ilar to those of controls, whereas late presymp-
tomatic subjects have shown altered expression
that resembles that of symptomatic HD patients;
(iii) these elevated mRNAs were significantly re-
duced in HD patients involved in a dose-finding
study of phenylbutyrate; and (iv) the expression
of the marker genes is significantly upregulated in
post mortem HD caudate, suggesting that alter-
ations in blood mRNAs may reflect disease mech-
anisms observed in HD brain.[171]
A phenylbutyrate dose-finding study in 21 sub-
jects with HD found that phenylbutyrate was safe
and well tolerated up to 15 g/day (maximum tol-
erated dose), while at 18 g/day, dose-limiting
toxicity emerged in 5 of 11 subjects with gait in-
stability, which was the most commonly reported
adverse event (observed in one-third of the sub-
jects) at all doses tested, and it was dose-limiting
in two subjects. At higher doses, other reported
toxicities were vomiting, lightheadedness, and
confusion. A gene expression assay was able to
detect a biologic response to the drug in peri-
pheral lymphocytes. These results provide safety
and dose-ranging data to support a phase II
clinical trial with phenylbutyrate in HD and re-
lated neurodegenerative disorders.[172]
5. Conclusions
HDACIs have been widely studied since they
seem to give the oppurtunity to manipulate gene
expression and, through it, they seem to be
promising to treat several pathologic conditions.
Apart from the previously described conditions,
recently, phenylbutyrate has also been inves-
tigated in Wilson disease, an autosomal recessive
disorder of copper homeostasis. Wilson disease is
caused by mutations in the gene encoding the cop-
per transporting P1B-type adenosine triphos-
phatase (ATPase) ATP7B, and, currently, more
than 300 different mutations have been described.
Treatment with phenylbutyrate and curcumin
has partially restored protein expression of most
ATP7B mutants (p.G85V, p.R778L, p.H1069Q,
p.C1104F, p.V1262F, p.G1343V, and p.S1363F).[173]
Phenylbutyrate has also been investigated re-
cently in deficiency in P-type ATP8B1 (caused by
autosomal recessive mutations in the gene en-
coding ATP8B1), a severe and clinically highly
variable hereditary disorder characterized by in-
trahepatic cholestasis. This condition is clinically
divided into progressive familial intrahepatic
cholestasis type 1 or intermittent, i.e. benign re-
current intrahepatic cholestasis type 1 disease. In
this study, it has been observed that a large pro-
portion of ATP8B1 mutations have resulted in
aberrant folding and decreased expression at the
plasma membrane, and, interestingly, these effects
have been partially restored by treatment with
phenylbutyrate. Therefore, according to the two
previously described studies, it has been pointed
out that pharmacologic chaperone may be an
important strategy in the future management of
hereditary liver disease in general.[174] A study
reveals that phenylbutyrate possesses chemical
chaperone activity in vitro, which prevents the
aggregation of denatured a-lactalbumin and bovine
serum albumin. The same authors investigated the
effects of phenylbutyrate on the accumulation of
Parkin-associated endothelin receptor-like receptor
(Pael-R), pathologically relevant to the loss of
dopaminergic neurons in autosomal recessive ju-
venile parkinsonism, showing that (i) phenyl-
butyrate restores the normal expression of Pael-R
protein and suppresses ER stress induced by the
overexpression of Pael-R; (ii) phenylbutyrate at-
tenuates the activation of ER stress-induced signal
transduction pathways and subsequent neuronal
cell death; and (iii) phenylbutyrate restores the vi-
ability of yeasts that fail to induce an ER stress
response under ER stress conditions. These find-
ings lead the author to conclude that phenyl-
butyrate suppresses ER stress by directly reducing
the amount of misfolded protein, including Pael-R
accumulated in the ER.[175]
A recent study has shown that 5-week admin-
istration of phenylbutyrate reverses spatial learn-
ing and memory deficits in an established mouse
model of Alzheimer disease, i.e. Tg2576 mice,
without altering b-amyloid burden. In addition,
the same authors have observed that transgenic
mice have showed a significant decrease in phos-
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phorylated tau in the hippocampus, after phe-
nylbutyrate treatment, which may be due to an in-
crease in the inactive form of the glycogen synthase
kinase 3b (GSK3b). A consistent decrease in brain
histone acetylation in the transgenic mice, which
may reflect an indirect transcriptional repression
underlying memory impairment, has also been
observed. The administration of phenylbutyrate
has restored brain histone acetylation levels and
activated the transcription of synaptic plasticity
markers, such as the selective glutamate recep-
tor (GluR)-1 subunit of the a-amino-3-hydroxy-
5-methyl-4-isoxazolepropionate (AMPA) receptor,
PSD95, and microtubule-associated protein-2. Ac-
cording to these results, phenylbutyrate may rep-
resent a new therapeutic agent to restore memory
function in AD.[176]
A recent experimental study showed using
both an in vivo and in vitro approach that phe-
nylbutyrate treatment may be successfully used to
reduce the plasma levels of neurotoxic branched-
chain amino acids and their corresponding a-keto
acids in a subset of maple syrup urine disease pa-
tients encouraging further studies of its long-term
efficacy.[177]
A recent study has also analyzed the efficacy of
phenylbutyrate on lipid-induced insulin resis-
tance and b-cell dysfunction in eight overweight
or obese nondiabetic men who were randomized
to undergo four studies each 4–6 weeks apart. Two
studies were preceded by 2 weeks of phenylbutyrate
(7.5g/day) orally, followed by a 48-hour intravenous
infusion of intralipid/heparin or saline, and two
studies were preceded by placebo treatment, fol-
lowed by similar infusions. It was observed that
lipid infusion reduced insulin sensitivity (S[I]), as
assessed by hyperinsulinemic-euglycemic clamps,
while it was significantly ameliorated by pretreat-
ment with phenylbutyrate. Absolute insulin secre-
tion rate (ISR), assessed by hyperglycemic clamps,
was not affected by any treatment. Phenylbutyrate
partially ameliorated the lipid-induced reduction
in the disposition index (DI= ISR·S[I]) pointing
out how phenylbutyrate prevented lipid-induced
b-cell dysfunction.[178]
Particularly in this review we have reported
the different clinical uses of phenylbutyrate, both
in vitro and in vivo, in lethal illnesses that do not
have any effective treatment. In our opinion, this
drug should be more widely and deeply inves-
tigated in the clinical area but, unfortunately, the
absence of viable international patents to protect
commercial use of themolecule reduces the chances
of financing new studies. Despite this frustrating
position, there is a wide speculative attention to
further investigate phenylbutyrate, even on an
anedoctical basis, and we definitely support this
challenge.
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